Vivos Therapeutics (VVOS) Operating Leases (2021 - 2026)

Vivos Therapeutics (VVOS) has 6 years of Operating Leases data on file, last reported at $3.7 million in Q1 2026.

• On a quarterly basis, Operating Leases rose 291.95% year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was $3.7 million, a 291.95% increase from a year earlier, with the FY2025 full-year figure at $3.8 million, up 271.01% from the prior year.
• Operating Leases for Q1 2026 stood at $3.7 million, down from $3.8 million in the prior quarter.
• Over the last five years, Operating Leases for VVOS reached as high as $3.8 million in Q4 2025 and fell as low as $932000.0 in Q1 2025.
• Historically, Operating Leases has averaged $2.1 million across 5 years, with a median of $1.9 million in 2023.
• Across the five-year window, Operating Leases plunged 50.48% in 2025 and surged 291.95% in 2026, its largest moves.
• Year by year, Operating Leases stood at $2.0 million in 2022, then fell by 23.72% to $1.5 million in 2023, then plunged by 31.95% to $1.0 million in 2024, then soared by 271.01% to $3.8 million in 2025, then slipped by 4.87% to $3.7 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $3.7 million in Q1 2026, $3.8 million in Q4 2025, and $2.9 million in Q3 2025.